Search results
Showing 61 to 75 of 133 results for nivolumab
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]
Awaiting development Reference number: GID-TA11111 Expected publication date: TBC
Tivozanib for treating advanced renal cell carcinoma (TA512)
Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.
Awaiting development Reference number: GID-TA11336 Expected publication date: TBC
Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Discontinued Reference number: GID-TA10126
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
Discontinued Reference number: GID-TA10221
Evidence-based recommendations on bevacizumab (Avastin [originator] and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.
Awaiting development Reference number: GID-TA11216 Expected publication date: TBC
Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562]
Discontinued Reference number: GID-TA10443
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]
Discontinued Reference number: GID-TA10321
Discontinued Reference number: GID-TA10233
Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]
Discontinued Reference number: GID-TA10158
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
Discontinued Reference number: GID-TA10151